NVIDIA Corporation vs. REGENERX BIOPHARMS INC
NVIDIA Corporation and REGENERX BIOPHARMS INC are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| NVDA | RGRX | |
|---|---|---|
| Market Cap | $5.65 trillion | — |
| Revenue (TTM) | $302.97 billion | — |
| Net Income (TTM) | $192.88 billion | — |
NVDA and RGRX split the size & scale factors evenly.
Valuation
| NVDA | RGRX | |
|---|---|---|
| P/E Ratio | 29.58 | — |
| Price / Book | 24.67 | — |
| Price / Sales | 18.65 | — |
NVDA and RGRX split the valuation factors evenly.
Profitability
| NVDA | RGRX | |
|---|---|---|
| Net Margin | 63.66% | — |
| Return on Equity | 84.23% | — |
NVDA and RGRX split the profitability factors evenly.
Dividend
| NVDA | RGRX | |
|---|---|---|
| Dividend Yield | 0.43% | — |
| Payout Ratio | 12.64 | — |
NVDA and RGRX split the dividend factors evenly.
Risk & Sentiment
| NVDA | RGRX | |
|---|---|---|
| Short Interest | 0.07% | — |
NVDA and RGRX split the risk & sentiment factors evenly.
Dig deeper: NVDA overview, NVDA financials, RGRX overview, RGRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.